Amlodipine induced Gingival Overgrowth in Patients at a Tertiary Level Hospital of Nepal
Vol. 2 No. 1 (2018), Research Article
Vol. 2 No. 1 (2018)

Amlodipine induced Gingival Overgrowth in Patients at a Tertiary Level Hospital of Nepal

Research Article
Published June 20, 2018
Dr. Arun Sharma
Dr. Rinku Joshi
Dr. Sweta Rajya Laxmi Rana
Dr. Dhan Bahadur Shrestha
Dr. Pramod Raj Joshi
Dr. Sitaram Khadka
PDF

Keywords

Amlodipine
drug induced gingival overgrowth
Nepal

Abstract

Background: Amlodipine is a commonly prescribed anti-hypertensive in clinical practice. Gingival overgrowth is a rare side effect of this drug; with a reported prevalence of 1.7-3.3% in literature. Gingival overgrowth can cause aesthetic and functional problems as well as cause hindrance to maintain proper oral hygiene, thereby deteriorating the periodontal condition of the patient. The prevalence of Amlodipine induced gingival overgrowth is poorly defined in our country.

Aim: This study aims to assess Amlodipine induced gingival overgrowth in a tertiary level referral hospital of Nepal Army.

Materials and Methods: This study was conducted on hypertensive patients with amlodipine therapy under regular follow up in the Department of Internal Medicine of Shree Birendra Hospital from September to December 2017. The data from record keeping was used for the study. Ethical clearance from Institutional Review committee of Nepal Army Institute of Health Sciences was obtained before conducting the study.

Results: Out of 507 patients taking amlodipine, 240 were eligible for study and six (2.5%) were found to have amlodipine induced gingival overgrowth. These patients were on a dose of 5-10 mg over six months to 25 years. The gingival overgrowth was correlated with dose and duration which was statistically significant (p<0.05).
Conclusion: Low prevalence of amlodipine induced gingival overgrowth and correlation with dose and duration was seen in this short-term study. However further large-scale follow-up studies may be required to assess the severity of the problem.

Keywords: Amlodipine; drug induced gingival overgrowth; Nepal.

PDF

References

Jorgensen MG. Prevalence of amlodipine-related gingival hyperplasia. J Periodontol. 1997;68:676-8.

Barclay S, Thomason J, Idle J, Seymour R. The incidence and severity of nifedipine-induced gingival overgrowth. J Clin Periodontol. 1992;19:311-4.

Ellis JS, Seymour RA, Steele JG, Robertson P, Butler TJ, Thomason JM. Prevalence of gingival overgrowth induced by calcium channel blockers: a community-based study. J Periodontol. 1999;70(1):63-7.

Marshall RI, Bartold PM. A clinical review of drug-induced gingival overgrowths. Aus Dent J. 1999;44:219-32.

Ellis JS, Seymour RA, Thomason JM, Monkman SC, Idle JR. Gingival sequestration of amlodipine and amlodipine-induced gingival overgrowth. Lancet. 1993;341:1102-3.

Carranza FA, Hogan EL. Gingival enlargement. In: Newman MG, Takei HH, Klokkevold PR, Carranza FA. Carranza’s Clinical Periodontology. 10th ed. St. Louis, MO: Saunders. 2006:375-6.

Hallmon WW, Rossmann JA. The role of drugs in the pathogenesis of gingival overgrowth: A collective review of current concepts. Periodontol 2000. 1999;21:176-96.

Ono M, Tanaka S, Takeuchi R, Matsumoto H, Okada H, Yamamoto H, et al. Prevalence of amlodipine-induced gingival overgrowth. Int J Oral-Med Sci. 2010;9(2):96-100.

Brown RS, Beaver WT, Bottomley WK. On the mechanism of drug-induced gingival hyperplasia. J Oral Pathol Med. 1991;20:201-9.

Tejnani A, Mani A, Sodhi NK, Mehta A, Gourkhede S, Thorat V, et al. Incidence of amlodipine-induced gingival overgrowth in the rural population of Loni. J Indian Soc Periodontol. 2014 Mar;18(2):226-8.

Seymour R, Ellis J, Thomason J, Monkman S, Idle J. Amlodipine-induced gingival overgrowth. J Clin Periodontol. 1994;21:281-3.

Seymour RA, Thomason JM, Ellis JS. The pathogenesis of drug induced gingival overgrowth J Clin Periodontol. 1996;23:165-75.

Dongari-Baqtzoglou A, Research, Science and Therapy committee, American Academy of Periodontology. Drug-associated gingival enlargement. J Periodontol. 2004 Oct;75(10):1424-31.

Banthia R, Gupta S, Banthia P, Singh P, Raje S, Kaur N. Is periodontal health a predictor of drug-induced gingival overgrowth? A cross-sectional study. Dent Res J (Isfahan). 2014 Sep;11(5):579-84.

Armitage GC. Development of a classification system for periodontal diseases and conditions. Ann Periodontol. 1999 Dec;4(1):1-6.

Samudrala P, Chava VK, Chandana TS, Suresh R. Drug-induced gingival overgrowth: A critical insight into reports from over two decades. J Indian Soc Periodontol. 2016;20(5):496-502.

Csiszar A, Weibe C, Larjava H, Hakkinen L. Distinctive Molecular Composition of Human Gingival Interdental Papilla. J Periodontol. 2007;78:2:304-14.

Bharti V, Bansal C. Drug-induced gingival overgrowth: The nemesis of gingiva unraveled. J Indian Soc Periodontol. 2013;17(2):182-7.

Parameter on periodontitis associated with systemic conditions. American Academy of Periodontology. J Periodontol. 2000 May;71(5Suppl):876-9.

Mavrogiannis M, Ellis JS, Thomason JM, Seymour RA. The management of drug-induced gingival overgrowth. J Clin Periodontol. 2006 Jun;33(6):434-9.